RVMDRevolution Medicines, Inc. Common Stock — stock analysis & sentiment

At $210.02, Revolution Medicines trades near the top of a 52-week band that runs from $39.73 to $224.31 — a range in which the low sits at roughly a fifth of the high. A spread that wide over a single year describes a stock that has been repriced dramatically rather than one that has drifted, and the current close sits within a few percent of the upper end of that band. A beta of 1.41 indicates it has tended to move more than the broader market in both directions.

The market capitalization stands at about $45 billion against a price-to-book multiple of roughly 28, and forward earnings are estimated as negative, which puts the forward P/E at -35.9 — a figure that reflects expected losses rather than a level that can be compared to a profitable peer. Profit margin is reported at zero. Taken together, these figures describe a business the market is valuing on future prospects rather than on current earnings, since there are no current earnings to price against.

Recent news flow is heavily company-specific and clustered in late August and early September 2026. The FDA approved RASONQUE (daraxonrasib) in metastatic pancreatic cancer on August 26, described as the first broad RAS-targeted medicine in that setting, followed the same week by a national pharmacy partnership for the drug and coverage noting the approval came a month after filing. On September 2, the New England Journal of Medicine published Phase 1/2 data on the same compound in metastatic non-small cell lung cancer. The remaining headlines concern securities class action deadlines at Erasca, a separate company, and relate to the wider oncology sector rather than to Revolution Medicines itself.